This review covers three areas in endometrial tumor pathology: International Federation of Gynecology and Obstetrics (FIGO) staging, the use of frozen section, and Lynch syndrome. The section on FIGO staging will emphasize problems that practicing pathologists often confront, such as measuring the depth of myometrial invasion, assessing for the presence of cervical stromal invasion, detecting low-volume lymph node metastases, and recognizing synchronous endometrial and ovarian tumors and artifacts. The frozen section portion of this review will focus on the performance characteristics of intraoperative examination of the uterus to determine tumor grade and depth of myometrial invasion, including suggestions for alternative methods. The last portion of this review will provide an overview of Lynch syndrome and a discussion of the rationale and methods of screening for Lynch syndrome. Modern Pathology (2016) 29, S59-S77; doi:10.1038/modpathol.2015.127 Pathologists no longer need to distinguish less than 50% myometrial invasion from no myometrial invasion; use peritoneal washing status to inform stage; or differentiate between endocervical mucosal and endometrial involvement by tumor. Despite these simplifications, many complexities and unanswered questions remain. FIGO staging ignores significant clinical heterogeneity within each substage. For example, a 70-year-old patient with serous carcinoma who has undergone a hysterectomy, without peritoneal or lymph node staging and with 40% myometrial invasion (FIGO stage I), has an estimated 5-year survival rate of 66%; the same patient with FIGO grade 1 endometrioid carcinoma, 30 negative lymph nodes, and no myometrial invasion (FIGO stage I) has an estimated 5-year survival rate of 97% (http://nomo grams.mskcc.org/Uterine/EndometrialSurvival.aspx).
provides the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging formulation for endometrial carcinoma and carcinosarcoma, 1 which is simplified from the 1988 classification. Pathologists no longer need to distinguish less than 50% myometrial invasion from no myometrial invasion; use peritoneal washing status to inform stage; or differentiate between endocervical mucosal and endometrial involvement by tumor. Despite these simplifications, many complexities and unanswered questions remain. FIGO staging ignores significant clinical heterogeneity within each substage. For example, a 70-year-old patient with serous carcinoma who has undergone a hysterectomy, without peritoneal or lymph node staging and with 40% myometrial invasion (FIGO stage I), has an estimated 5-year survival rate of 66%; the same patient with FIGO grade 1 endometrioid carcinoma, 30 negative lymph nodes, and no myometrial invasion (FIGO stage I) has an estimated 5-year survival rate of 97% (http://nomo grams.mskcc.org/Uterine/EndometrialSurvival.aspx).
Given this example, it becomes apparent that the current FIGO staging system does not take into account the distinctiveness of each type of endometrial carcinoma or staging adequacy. We recently reported a proposal for substaging uterus-confined endometrial carcinoma that recognizes disease type and grade, as well as staging adequacy. 2 This yields significantly more predictive information than does either the FIGO 1988 or FIGO 2009 systems, with uterus-confined unstaged serous or FIGO grade 3 carcinomas having the worst prognosis and patients with well-staged FIGO grade 1 endometrioid carcinomas having the best outcome. This system also fails to recognize the importance of different modes of dissemination, suggesting that lymphovascular and peritoneal spread, direct extension, and implantation without invasion are clinically equivalent. Furthermore, FIGO 2009 does not indicate whether lymphovascular tumor emboli in ovarian hilar vessels should be considered stage III disease, nor does it define cervical stromal invasion. Several other challenges pathologists face when trying to implement the FIGO 2009 staging system have been discussed. [3] [4] [5] 
Myometrial Invasion
Assessment for the presence and depth of myometrial invasion can be difficult. Several studies have reported interpathologist discrepancy rates of~30%, with gynecological pathologists tending to report smaller measurements than non-specialized pathologists. [6] [7] [8] [9] We have found that overcalling the presence and depth of myometrial invasion can be attributed to irregular endomyometrial junction, inapparent and metaplastic endometrial stroma, and measuring tumor thickness rather than depth. To reiterate, the location of the endomyometrial junction must be ascertained or at least estimated to avoid measuring tumor thickness, particularly when the tumor is exophytic. Even if the tumor is massive and protrudes into the endometrial cavity, this does not justify measuring its thickness and reporting that measurement as the depth of myometrial invasion ( Figure 1 ). The less commonly encountered undercalls are related to unfamiliarity with less common invasion patterns: 'microcystic elongated and fragmented' (MELF) and 'adenoma malignum-like.' Figure 2 illustrates the methodology for measuring depth of myometrial invasion. One must take into account the fact that most uteri have an irregular endomyometrial junction. This interface can be assessed at low power and recognized as intact when the contour is rounded, there is endometrial stroma at the interface with myometrium, and a stromal response to invasion is lacking. The same rules apply to the distinction of adenomyosis colonized by adenocarcinoma from myometrial-invasive adenocarcinoma. A particular problem involves the appearance of altered endometrial stroma, which may be composed of spindly eosinophilic cells that resemble myometrium. Failure to recognize this type of stroma might lead to an erroneous diagnosis of myometrial invasion. Examination at high power usually reveals seamless transitions from typicalappearing endometrial stroma and a contrast between the fibrillary appearance of altered stroma and the well-organized bundles of myometrium ( Figure 3 ). Another uncommon problem that is not addressed by the FIGO system is how to categorize a focus of deeply placed myometrial invasion that is discontinuous with the overlying endomyometrial junction and situated close to a focus of adenomyosis colonized by adenocarcinoma ( Figure 4 ). My approach to this scenario is to report the depth of myometrial invasion by measuring the distance between the invasive focus and the adjacent area of adenomyosis. Although this has not been studied specifically, due to its rarity, it is hard to imagine that 10 cells of myometrial-invasive carcinoma deep in the myometrium has the same clinical implication as a mass of millions of tumor cells arranged contiguously from the overlying endomyometrial junction to the deepest focus.
'MELF' and 'adenoma malignum-like' invasion patterns are not difficult to recognize once a few basic guidelines are considered (Figures 5 and 6 ). MELF pattern invasion [10] [11] [12] [13] [14] [15] [16] [17] is usually first detected at scanning magnification because of its tendency to elicit an obvious myxoinflammatory myometrial response to invasion. The neoplastic epithelial cells may be difficult to distinguish at first, because they tend to be obscured by the stromal response ( Figure 7 ). The cells that constitute the invasive foci also differ in appearance when compared to adenocarcinoma in the endometrial compartment. They are frequently squamous metaplastic, elongated with attenuated cytoplasm and, paradoxically, may also have a histiocyte-like appearance with a low nuclear-to-cytoplasmic ratio. The cytoplasmic Tumor confined to the uterus; ½ or more myometrial invasion II:
Cervical stromal invasion, but not beyond uterus IIIA:
Tumor invades serosa or adnexa IIIB:
Vaginal and/or parametrial involvement IIIC1: Pelvic node involvement IIIC2: Para-aortic involvement IVA:
Tumor invasion bladder and/or bowel mucosa IVB:
Distant metastases including abdominal metastases and/ or inguinal lymph nodes attenuation may mimic the appearance of endothelial cells, such that distinction between myometrial invasion and lymphovascular invasion becomes difficult. Furthermore, when there is true lymphovascular invasion, a frequent finding in MELF invasion, the intravascular tumor cells may retain a histiocytoid appearance, unlike most of the overlying tumor ( Figure 8 ). MELF invasion is Figure 2 Assessment of myometrial invasion. (a) Direct invasion from the endometrium is the most recognizable and reproducible form of invasion, particularly when the advancing front is jagged and associated with a stromal response. In this situation, the depth of invasion is measured from the nearest adjacent uninvolved endomyometrial junction to the deepest focus of invasion. (b) Discontinuous myometrial invasion; ensure the discontinuous focus is invasive (illustrated by spiculated contours), not adenomyosis colonized by carcinoma (illustrated by rounded contours in c-e). (c and d) Depth of invasion in these cases is measured from a virtual plane whose location is estimated from the adjacent endomyometrial junction. In c, the invasive focus is represented by a broad, pushing front, a pattern that is difficult to evaluate. Pushing invasion can often be recognized by the presence of a stromal response at the leading edge. In d, the invasive focus is mostly discontinuous; the discontinuous focus of myometrial invasion can be distinguished from adenomyosis because of its spiculated shape. Histologically, the lack of endometrial stroma and the presence of surrounding desmoplasia are the two most helpful features that indicate myometrial invasion is present. (e) Rarely, carcinoma may arise in adenomyosis or invade from a deep focus of adenomyosis. In this situation, the depth of invasion should be measured from the junction of the adenomyosis and myometrium to the deepest area of invasive carcinoma. (This figure was published in Uterine Pathology, Copyright Cambridge University Press, 2012). statistically associated with lymphovascular invasion and metastasis to regional lymph nodes, but it
has not yet been shown to be an independent prognostic indicator. MELF has been shown to be a consequence of epithelial-to-mesenchymal transition present at the invasive front of endometrial carcinomas, with the loss of epithelial cell adhesion molecules such as E-cadherin. 11, 12, 16 It is possible that this pattern is over-represented in tumors with defective MLH1 expression. 18 The adenoma malignum-like invasion pattern displays variable numbers of well-formed endometrioid glands haphazardly distributed throughout the myometrium, but a stromal response to invasion is either minimal or absent. 14, 19 This can be distinguished from adenomyosis by virtue of the chaotic arrangement of neoplastic glands, rather than the focal or multifocal clustered neoplastic glands surrounded by endometrial stroma that is characteristic of adenomyosis. The adenoma malignum-like pattern of invasion probably does not have prognostic significance when compared with tumors with conventional forms of myometrial invasion. It should also be noted that despite this entity's name, it bears no clinical or pathological relationship to minimal deviation adenocarcinoma of the endocervix. The only feature that adenoma malignum-like invasion shares with minimal deviation adenocarcinoma of the endocervix is the presence of invasive well-differentiated glands without an accompanying stromal response.
Lymphovascular Invasion
The recognition of lymphovascular invasion is usually straightforward. Both the presence of lymphovascular invasion and its extent are prognostically important. Foci of lymphovascular invasion should be sought at the advancing edge of the tumor as it invades myometrium. Occasionally, with serous carcinomas, one can confidently diagnose lymphovascular invasion within an endometrial polyp or within endometrial stroma. Otherwise, foci suspicious for lymphovascular invasion should not be interpreted as being 'positive for lymphovascular invasion' when intravascular tumor is found within the tumor itself. Distinction of the pseudoendothelial appearance of MELF from true lymphovascular invasion can be accomplished with one of the endothelial immunohistochemical markers, such as FLI-1, podoplanin, and/or CD31.
One of the most challenging differential diagnoses involves distinguishing lymphovascular invasion from artifactual tissue displacement ( Figure 9 ). It has been reported that artifactual tissue displacement into myometrial vessels, spaces not lined by endothelium, fallopian tube lumen, and peritoneal washings is seen more commonly in laparoscopic and robotic operative procedures compared with open, or traditional, operative approaches. [20] [21] [22] [23] [24] Although the phenomenon was originally considered solely a result of uterine manipulation and tumor fragmentation, it has also been reported that both surgeons and pathologists are responsible for this artifactual phenomenon. It is currently thought that uterine manipulation and tumor fragmentation resulting from the operative procedure presents the pathologist with friable tumor that can be dragged through the tissue during prosection. Fixation for several hours in formalin before prosection has been shown to minimize the occurrence of these artifacts. 21 Clues pointing to the presence of artifact include finding neoplastic and non-neoplastic endometrium, oftentimes crushed and distorted, as well as stroma in vessels and non-endothelial-lined spaces of varying sizes close to the tumor and in distant sections. Occasionally, it may be impossible to confidently diagnose lymphovascular invasion in the presence of such artifact.
Cervical Involvement
Impediments to an accurate diagnosis of cervical stromal invasion are largely due to the absence of anatomical boundaries, or definitions thereof that rigidly separate cervix from lower uterine segment and endocervical mucosa from cervical stroma ( Figures 10 and 11 ). These are some of the types of distinctions responsible for disappointing rates of interobserver agreement. 25, 26 One can be confident that cervical involvement is present when the neoplastic focus is bounded on two sides by normal endocervical glands (proximally and distally), and that stromal invasion is present when the invasive focus underlies normal ectocervix or endocervical glands. Tumors placed at the junction of the endocervix and lower uterine segment cannot be said to involve cervix with certainty when the tumor involves lower uterine segment and is bounded by endocervical tissue only distally. It can also be difficult to distinguish extensive endocervical mucosal involvement from cervical stromal invasion. An example of such a problematic case is a low-grade endometrioid adenocarcinoma that is exophytic or obscures normal endocervical mucosal landmarks but does not invade underlying stroma, and in which no stromal response to invasion is present (summarized in Figure 12 ). Thus, either irregular infiltration into stroma deep to the tumor or a stromal response at the pushing edge of the lesion would be required to diagnose cervical stromal invasion ( Figure 13 ). In addition to these guidelines, it remains important to accurately distinguish embryological remnants and endocervical hyperplasias from endometrioid adenocarcinomas that involve cervical stroma with an adenoma malignum-like invasion pattern, 27 as described earlier in this review. I believe in applying a high threshold for diagnosing cervical stromal invasion, as there are some recent data that suggest cervical stromal invasion alone is not independently associated with clinical outcome. 28 Rather, it is possible that cervical stromal invasion co-exists with other factors known to influence poor outcomes, such as deep myometrial invasion, high tumor grade, and the presence of lymphovascular invasion. Of note, rare endometrioid adenocarcinomas preferentially invade cervical stroma over myometrium, such that the location of the invasion does not inform the tumor type or primary site. 27 Similarly, rare endocervical adenocarcinomas colonize lower uterine segment and the uterine corpus epithelium 29 and may preferentially invade stroma and myometrium in those sites. Distinction between an endocervical adenocarcinoma preferentially involving corpus and an endometrioid adenocarcinoma preferentially involving cervix may require the use of immunohistochemistry.
Synchronous Endometrial and Ovarian Carcinoma
The coexistence of adenocarcinoma in endometrium and ovary presents difficulties for stage assignment, prognostication, and therapy. Synchronous adenocarcinomas of ovary and endometrium should be staged separately (usually FIGO stage I in each site), whereas metastasis from endometrium to ovary should be designated endometrial carcinoma, FIGO stage III. Guidelines were initially developed with the idea that synchronous tumors should behave as two low-stage tumors rather than one high-stage tumor. In other words, the guidelines segregate tumors into one clinically indolent category (i.e., 'synchronous') and another potentially aggressive category (i.e., 'metastatic'). Specifically, guidelines were not developed by determining clonal relationships between tumors in endometrium and ovary; in fact, several investigators have reported clonal relationships between 'synchronous' endometrial and ovarian carcinomas. [30] [31] [32] Although such tumors may represent metastatic tumors from a genotypic perspective, there is as yet no clinical evidence that shared clonality in this context has clinical value.
There are two characteristic types of synchronous endometrial and ovarian carcinomas. The most common occurs in young patients, with paradoxically histologically identical tumors in both sites, and a large, unilateral ovarian tumor. [33] [34] [35] [36] [37] [38] Table 2 summarizes the guidelines for recognizing synchronous endometrial and ovarian carcinoma when histology is similar in both organs. Most of these tumors are sporadic, although a small percentage is attributable to Lynch syndrome. 39 The less common type of synchronous carcinoma involves tumors of different types or, perhaps, grades. A good number of these tumors are attributable to Lynch syndrome, particularly when either pure or mixed clear cell carcinoma is present in either site. 40, 41 For endometrial endometrioid carcinomas, typical patterns of metastasis to ovaries include bilateral involvement measuring o 10 cm, ovarian surface involvement, and a nodular growth pattern that preserves ovarian stroma between nodules (Table 3 ). For serous carcinomas that involve endometrium and ovary, most pathologists default to a diagnosis of metastasis from endometrium to ovary, especially when the volume of tumor in endometrium exceeds that in ovary, but this paradigm will probably change as we gain a better understanding of the specificity of WT1 immunostaining and intraepithelial serous carcinoma in endometrium and/or fallopian tube. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] Along these lines, there is now increasing interest in being able to recognize 'drop metastasis' of serous carcinoma from uterine adnexa to uterine corpus or cervix ( Figure 14 ). There is little evidence supporting the idea that synchronous serous carcinomas of endometrium and ovary exist in any significant numbers. Table 4 summarizes guidelines for diagnosing endometrial serous carcinoma metastatic to ovary(ies) and Table 5 summarizes guidelines to recognize drop metastases (metastasis from ovarian or fallopian tube serous carcinoma to endometrium or cervix). Note that Tables 2,3 ,4 and 5 present guidelines rather than diagnostic criteria. In many cases, it is impossible to distinguish synchronous from metastatic patterns with certainty. Given the following example, it is extremely difficult to assign the tumor to either category: a deeply invasive FIGO grade 1 endometrioid adenocarcinoma of endometrium with a large, unilateral ovarian tumor involving ovarian surface in an older woman. A good practice is to list the features supporting synchronous or metastatic disease and inform the clinician that a more precise diagnosis cannot be made based on the evidence at hand.
Lymph Node Metastasis
It is usually easy to determine when endometrial carcinoma is present in lymph nodes, but interest in MELF invasion, the appearance of associated histiocyte-like tumor cells in lymphatics and subcapsular sinuses, 55 and the increasing use of cytokeratin immunohistochemistry for ultrastaging sentinel lymph nodes have made this issue more challenging ( Figure 15 ). Ultra-staging with cytokeratin immunohistochemistry has revealed a small, but troublesome, number of cases with low-volume metastases, including single keratin-positive cells, isolated tumor cells, and micrometastases, using definitions from breast pathology. [56] [57] [58] [59] [60] [61] Although many pathologists and gynecologists consider these scenarios to represent FIGO stage IIIC endometrial carcinoma, some caution is warranted. Interestingly, isolated tumor cells tend to be associated with clinically stage I, FIGO grade 1 endometrioid adenocarcinoma with or without MELF invasion, which in the absence of isolated tumor cells would be considered low-or, at most, intermediate-risk disease. This contrasts with the far more common situation in which FIGO stage IIIC disease is seen in conjunction with high-grade tumor, nonendometrioid histology and, frequently, extensive myometrial invasion. Aside from the uncertain clinical significance of isolated tumor cells in otherwise low-risk disease, considering these patients to have FIGO stage IIIC carcinoma may contaminate a category about which much is known and where the delivery of adjuvant therapy constitutes the standard of care. It is therefore considered controversial by some pathologists whether to use ultrastaging to identify low-volume metastases.
Frozen section
Frozen section to determine tumor grade and depth of myometrial invasion is used to guide the sampling of lymph nodes for therapy and prognostication. This is a very familiar concept for US pathologists, although it is used less frequently in other parts of the world. Frozen section performed for this purpose is time consuming, may be inaccurate in as many as 15% of cases, 7-9 introduces artifacts by serial sectioning before formalin fixation, is justified by data that have been accrued in the postoperative setting (rather than pre-or intraoperatively), and is applied in an empirical fashion by gynecologists. A hysterectomy (i.e., postoperative) diagnosis of myometrial-invasive FIGO grade 2 or grade 3 carcinoma places the patient into an intermediate-to-high clinical risk category (i.e., the patient may have lymph node metastases), as does 450% invasion when the tumor is FIGO grade 1. 62, 63 Tumor size assessed intraoperatively is also used in one popular algorithm. 64 This information has been used to guide the performance of lymph node dissection after intraoperative examination.
The decision to request frozen section and how to use the data also vary by surgeon. This is due to a lack of consensus in the gynecology community regarding whether lymph node dissection is therapeutic, whether lymph node sampling can replace lymph node dissection, and what constitutes an adequate lymph node dissection. Many gynecologists also work under the erroneous impression that the distinction between FIGO grades 1 and 2 is reproducible and has the same significance in the pre-and intra-operative setting as it does in the postoperative setting; they also tend to believe that the assessment of the depth of myometrial invasion is reproducible. Review of the pertinent literature indicates that lymph node dissection is not therapeutic, 65, 66 but it is preferable to lymph node sampling, 67,68 as a more accurate tumor stage can be ascertained. In some studies, adequate lymph node staging is set at approximately 10-15 lymph nodes, 69, 70 although the requirement to dissect paraaortic lymph nodes in addition to pelvic lymph nodes in every case is still controversial. Without knowing a patient's lymph node status, there is indeed a relationship between tumor grade and depth of invasion and, secondarily, with lymph node metastasis, but once a formal surgical stage is assigned, the clinical meaning of separating FIGO grades 1 and 2 loses value. 71 Intraoperative macroscopic evaluation of the depth of myometrial invasion is even less accurate than frozen section [72] [73] [74] [75] [76] [77] and similarly introduces artifact.
Most frozen sections to determine depth of invasion are performed in patients with a known diagnosis of atypical hyperplasia/endometrial intraepithelial neoplasia (EIN) or FIGO grade 1 endometrioid adenocarcinoma, because these neoplasms are the most common and the extent of myometrial invasion, if present, informs the decision to perform lymph node sampling or dissection. Despite the fact that between 5 and 15% of these neoplasms show substantially invasive carcinoma at frozen section, only 2% metastasize to lymph nodes. 62, 78, 79 Given a hypothetical group of 100 patients with endometrial cancer, one would have to perform 100 frozen sections (including preparation of as many as 200 frozen tissue blocks or more) and up to 15 lymph node dissections to find the 2 patients who might be more accurately staged by having had a lymph node dissection performed. Whether these 2 patients necessarily benefit from adjuvant therapy is unknown, but some gynecologists estimate that the use of adjuvant therapy in this setting might prevent 50% of recurrences, thereby possibly benefitting 1 of 100 theoretical patients. These findings have led to the development of alternatives to frozen sections.
Two alternatives obviate the need for frozen section: performance of lymph node dissection in every patient, without regard to pre-operatively assessed tumor type or grade, and the use of sentinel lymph node mapping. Performing lymph node dissection for every patient with endometrial cancer has met considerable resistance because of the risk of lower extremity lymphedema, 80 cost, increased operative time, need for a gynecologic oncologist instead of a generalist, and the number of blocks and slides generated. The sentinel lymph node mapping procedure therefore appears most attractive. Patients undergoing this procedure [56] [57] [58] [59] [60] [61] are accurately staged (at least in~90%) without lymphadenectomy and are spared the risk of lymphedema. Before the procedure, blue dye and/or a tracer is injected into the lower uterine segment. Mapping at the time of surgery reveals the sentinel node(s). These lymph nodes are removed along with any enlarged lymph nodes and all blue dye/tracer-negative lymph nodes that are contralateral to sentinel lymph nodes. 59 Frozen section is not performed because there is no intraoperative question to answer. The sentinel lymph nodes are breadloafed at 2-mm intervals and entirely submitted for microscopy. At Memorial Sloan Kettering Cancer Center, two hematoxylin and eosin (H&E) slides are prepared, separated by 50 microns. Unstained slides corresponding to each H&E level are prepared, and one pan-cytokeratin immunohistochemical stain is performed at each level (i.e., two immunostained slides separated by 50 microns). Unlike the previous paradigm in breast cancer, patients are not brought back to the operating room for completion of the dissection when sentinel lymph nodes are positive for carcinoma. Problems with implementation, however, involve challenges with accurate mapping in patients with high body mass indexes (BMIs) and when the surgeon has insufficient experience with the mapping procedure. From the pathology perspective, one confronts problems when undue reliance is placed upon the use of cytokeratin immunohistochemical stains to detect low-volume metastasis, particularly because it has not been shown that survivals are comparable to macrometastasis (i.e., 42 mm) that can be visualized without immunohistochemistry. Other considerations are the theoretical possibility of mistaking benign mesothelial cells and Mullerian inclusions for low-volume metastatic carcinoma, and many pathology practices are reluctant to perform more immunohistochemical stains, as reimbursements for this procedure are limited. Therefore, it may be reasonable to forego the use of cytokeratin immunohistochemistry for ultrastaging, provided that multiple recut sections are examined carefully.
Lynch syndrome
In women with Lynch syndrome, the risk of developing endometrial and ovarian cancer exceeds that of colorectal cancer; and in patients who develop both gynecological and intestinal carcinomas, a small majority develops gynecological cancer first. 81 Identifying which endometrial cancer patients have Lynch syndrome saves lives by instituting surveillance colonoscopies in affected patients and relatives; it has been reported that surveillance for colorectal carcinoma in known Lynch syndrome patients reduces mortality from colorectal carcinoma by 65%. [82] [83] [84] Performing prophylactic hysterectomy and bilateral salpingo-oophorectomy in known carriers is also advantageous. Although Lynch syndrome is somewhat heterogeneous, there are some important general differences between Lynch syndrome-associated [85] [86] [87] [88] [89] [90] and sporadic endometrial cancer (Table 6 ). Patients with Lynch syndromeassociated endometrial carcinoma are younger and have lower BMIs. The prognostic and therapeutic implications of Lynch syndrome-associated endometrial carcinoma are, as of yet, uncertain. Between 2 and 5% of endometrial carcinomas are attributable to Lynch syndrome. Although the incidence of Lynch syndrome increases with age, the prevalence decreases significantly because of the strikingly increased incidence of sporadic endometrial carcinoma as patients age. Nevertheless, it has been reported that~10% of patients with endometrial carcinoma under 40 years of age have Lynch syndrome.
Lynch syndrome is currently diagnosed in the presence of one of the following: (1) germline mutation of one of the DNA-mismatch repair genes (MLH1, PMS2, MSH2, and MSH6); (2) germline EPCAM mutation; and (3) constitutive epimutation. The first scenario, germline mutation of one of the DNA-mismatch repair genes, is by far the most commonly encountered abnormality among Lynch syndrome patients. A carrier has one copy of a defective DNA-mismatch repair gene in somatic cells throughout her body. A second 'hit' occurs in the target organ, such as the endometrium, leading to loss of a functioning DNA-mismatch repair protein, thereby interfering with physiologic DNA-mismatch repair. DNA-mismatch repair is accomplished by two sets of heterodimers, MLH1 with PMS2 and MSH2 with MSH6. Loss of a functioning DNAmismatch repair protein almost always results in the loss of immunohistochemical expression of the correspondingly mutated DNA-mismatch repair protein, and usually also its partner (i.e., MLH1 along with PMS2; and MSH2 along with MSH6). Loss of a functioning DNA-mismatch repair protein is also usually followed by the acquisition of multiple microsatellites that do not match those present in tissues unaffected by cancer (microsatellite instability (MSI)). Germline EPCAM mutation leads to downregulation of MSH2 with similar downstream effect as when the MSH2 gene is mutated, while constitutive epimutation involves widespread methylation of genes throughout the body, including MLH1, the consequence of which is similar to sporadic MLH1 methylation or mutation. Currently, Lynch syndrome can therefore only be diagnosed by studying tissues unaffected by carcinoma, such as blood, because these would contain the germline mutations that define the entity without all of the secondary changes acquired by the tumor in the target site.
Regarding the heterogeneity of Lynch syndrome, it should be noted that the gene mutation present has important implications. Mutation type is associated with the relative risk of developing endometrial carcinoma and extra-gynecologic cancers, the age at which carcinoma develops, and easily detected MSI. [85] [86] [87] [88] [89] [90] Mutations in MSH6 are more prevalent in Lynch syndrome-associated endometrial carcinoma than in Lynch syndrome-associated colorectal carcinoma, and this accounts for some of the differences between them (Table 7) . For example, MSH6 germline mutation carriers present at an older age and tend to develop endometrial carcinoma more often than colorectal carcinoma. This indicates that the approach to Lynch syndrome screening in endometrial cancer should differ from that in colorectal cancer. The average patient with Lynch syndromeassociated endometrial carcinoma is older than someone with Lynch syndrome-associated colorectal carcinoma, more likely to have an MSH6 mutation, less likely to have an MSI-high (MSI-H) tumor, and less likely to have a personal or family history of Lynch syndrome-associated carcinomas.
Although it is currently not feasible to perform germline sequencing to detect mutated DNAmismatch repair genes in every endometrial carcinoma patient, universal germline sequencing, requiring patient consent, may become the standard Lynch syndrome workup. In the interim, we will rely on the use of immunohistochemistry to detect DNA-mismatch repair proteins (DNA MMR IHC). It has been shown that DNA MMR IHC is~90% sensitive and 90% specific for a DNA-mismatch repair abnormality; [90] [91] [92] [93] and as of 2009, DNA MMR IHC followed by targeted germline sequencing was the most efficient and cost-effective way to determine which endometrial cancer patients have Lynch syndrome. 91 For example, if DNA MMR IHC shows loss of expression of MSH2 and MSH6, the germline sequencing will focus on those genes specifically, without having to sequence MLH1 and PMS2. Thus, DNA MMR IHC is an indirect way of screening for Lynch syndrome because confirmatory germline testing is still required for a Lynch syndrome diagnosis.
Why is DNA MMR IHC only an indirect direct test for Lynch syndrome? DNA MMR IHC detects almost any abnormality in DNA MMR gene expression, whether or not the insult is germline (i.e., due to Lynch syndrome). In fact, 20-30% of endometrial carcinomas are MSI-H and show abnormal DNA MMR IHC, yet only 2-5% of patients have Lynch syndrome, as mentioned previously. The most common reason for DNA MMR IHC abnormal/no germline DNA-mismatch repair mutation is methylation of the MLH1 promoter, found only in the target organ's cancer. Comparatively less is known about the occasional somatic DNA-mismatch repair mutation found only in the target organ's cancer. If a cancer cell harbors one allele with a somatic DNAmismatch repair mutation, a second hit needs to occur before damaging the DNA-mismatch repair system. In many cases, a second somatic DNAmismatch repair mutation occurs.
It is debatable whether or not to test all endometrial cancers with DNA MMR IHC or to restrict immunohistochemical testing to certain categories of patients and carcinomas (i.e., selective screening). There is a growing consensus that, if resources permit, all endometrial carcinomas should undergo DNA MMR IHC testing because most selective screening schemes fail to detect all Lynch syndrome-associated endometrial carcinomas. 94, 95 To limit resource expenditure, an age limit, perhaps 65 years, can be set, beyond which the ratio of Lynch syndrome-associated endometrial carcinoma to sporadic endometrial cancer falls precipitously and to use a two-marker DNA MMR IHC panel (i.e., MSH6 and PMS2) rather than the more traditional four-marker panel (MLH1, PMS2, MSH2, and MSH6). 94 To limit resource expenditure further, (Table 8 ; Figures 16,17,18 ), which has been validated externally. 96 This algorithm utilizes DNA MMR IHC testing in all endometrial cancers from patients younger than 50 years of age, when the personal or family history suggests Lynch syndrome and when a one of a variety of different tumor morphological and topographic features is present. The important morphological and topographic features that appear in this algorithm have been described in a series of Lynch syndromeassociated and MSI-H endometrial carcinomas. The general rule is as follows: as more restrictions are placed on screening and the lower the resource expenditure, the more Lynch syndrome patients will go unrecognized. Loss of DNA-mismatch repair expression in tumor cell nuclei is equated with an abnormal DNA MMR IHC result. To score this pattern properly, there should be no tumor cell nuclear staining and an intact internal positive control, usually provided by non-neoplastic stromal cells, endothelium, and tumor-infiltrating lymphocytes ( Figure 19 ). Table 9 displays the most common abnormal DNA MMR IHC staining patterns, listed in order of decreasing frequency. Of note, the most common patterns involve loss of expression of two proteins together, either MLH1/PMS2 or MSH2/MSH6. Less frequently, one finds abnormal PMS2 with intact MLH1 or abnormal MSH6 without PMS2, all of which supports the use of a two-marker DNA MMR IHC panel consisting of PMS2 and MSH6 alone. Table 10 lists some common pitfalls in interpreting DNA MMR IHC. The two most common are the following: distinguishing weak or equivocal staining from abnormal staining (Figure 20 ) and misinterpreting DNA-mismatch repair-intact tumor-infiltrating lymphocytes as tumor cells with intact DNA-mismatch repair staining (Figure 21 ). In the first instance, one should repeat the stain, show the stain to a knowledgeable colleague, study the immunohistochemistry for the partner protein (i.e., look at PMS2 if the MLH1 is equivocal), and/or choose another tumor block for staining. If the results remain equivocal, it is better to report the result as inconclusive rather than choosing either 'normal' or 'abnormal.' Distinguishing tumor-infiltrating lymphocytes from tumor cells is generally straightforward once one is aware of this type of pitfall. If one is unsure, leukocyte common antigen immunohistochemistry should be considered.
When the DNA MMR IHC shows abnormal MLH1 and PMS2 expression, the most commonly encountered abnormal staining pattern, germline genetic testing should not be undertaken without first performing an MLH1 promoter methylation assay, as seen in Figure 22 . Since the presence of MLH1 promoter methylation in the tumor signifies that the patient is at lowest risk of having Lynch syndrome, germline genetic testing is generally not performed. This underscores another important difference between MSI-H endometrial and colorectal carcinomas that are not Lynch syndrome associated. Most MSI-H colorectal carcinomas that are not associated with Lynch syndrome also have BRAF mutations that can be ascertained with immunohistochemistry or somatic mutation (tumor) testing. The MLH1 promoter methylation assay takes the place of BRAF testing in MSI-H endometrial carcinoma because BRAF mutations are only rarely found in endometrial cancers. The development of a comprehensive screening system for Lynch syndrome obviously warrants a committed multidisciplinary approach. As we developed our institutional system, we sought advice and collaboration from medical-legal experts, clinical geneticists, gynecologic surgeons, medical oncologists, and pathologists. The appendix found at the end of this article shows a summary of the barriers to the identification of endometrial cancer patients with Lynch syndrome and underscores ways in which even a coordinated and motivated team may miss identifying Lynch syndrome patients. A 'one size fits all' approach to Lynch syndrome screening is most likely not appropriate, but the complexity of any system that is developed requires open lines of communication, compliance audits, and further refinements as practitioners learn more about Lynch syndrome. It is uncertain whether or not this collaborative approach can succeed in low-volume practices and in settings where interdisciplinary teams do not exist or are not highly functional. At a minimum, compliance audits must demonstrate that, regardless of the screening paradigm used, all applicable tumors are tested and all abnormal results are reported to physicians and/or clinical geneticists who can make the best use of the information.
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e. Some centers do selective DNA-mismatch repair testing, using patient age, clinical history, tumor morphology, and tumor topography as criteria. Our institutional experience supports continuing our own paradigm, although we acknowledge a number of imperfections. Using a selective approach to testing results in failing to test an occasional LS patient whose age, clinical history, and tumor characteristics do not meet criteria for testing. Another problem is exemplified by a patient whose tumor should have undergone DNA MMR IHC testing according to the selection criteria but was not tested. We currently perform monthly quality assurance checks to catch the latter examples. f. DNA MMR IHC is~90% sensitive, which means that there is always going to be at least a 10% miss rate if the sole screen is immunohistochemistry, whether performed universally or in a selective manner.
Problems with reporting
a. The immunohistochemistry report may accompany the main biopsy or hysterectomy report or may be issued as an addendum (issued a few days after the main pathology report). Not finding the report, not finding the report at the right time, and having the wrong person find the report are all barriers. Examples include the following: the clinician does not compulsively check the electronic medical record every day in order to find the addendum report; the report is generated after the patient's first follow-up visit; and the surgeon gets the report, but in many instances, this is not the best person to interpret the report and convey the information to the patient. We have a new quality assurance audit that makes sure that every patient with an abnormal report is contacted by a clinical geneticist. A formal clinical genetics consultation is scheduled only after any necessary ancillary tests are performed (i.e., MLH1 promoter methylation testing) and the patient is motivated to attend the consultation. b. There are problems with the terminology used in immunohistochemistry reports. Most DNA MMR IHC reports avoid the use of the terms 'LS' and 'germline genetic testing' because then regulators could argue that DNA MMR IHC is a germline genetic test that requires patient consent. The report usually talks about 'lost' or 'retained' expression of DNA-mismatch repair proteins, the subtleties of which may be lost on the recipient. 
